Several studies have shown that for patients with identifiable KRAS mutations in their tumor tissue, the corresponding mutations can be detected in DNA isolated from plasma, and elevated ctDNA levels have been associated with decreased overall 2-year survival [4, 17, 18]. Here, KRAS is linked to neoplasm.